GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Debt-to-Revenue

NKGen Biotech (NKGen Biotech) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

NKGen Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $11.72 Mil. NKGen Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $10.50 Mil. NKGen Biotech's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

NKGen Biotech Debt-to-Revenue Historical Data

The historical data trend for NKGen Biotech's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Debt-to-Revenue Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Revenue
122.00 156.29 N/A

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Competitive Comparison of NKGen Biotech's Debt-to-Revenue

For the Biotechnology subindustry, NKGen Biotech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Debt-to-Revenue falls into.


NKGen Biotech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

NKGen Biotech's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(9.991 + 9.93) / N/A
=N/A

NKGen Biotech's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(11.719 + 10.495) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

NKGen Biotech Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech (NKGen Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Debt-to-Revenue
Comparable Companies
OCUP CASI SPRO XLO NGM GBIO ASMB CCCC OCEA FIXX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
Website
https://www.nkgenbiotech.com
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.